Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

about

Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Item

http://www.wikidata.org/entity/Q47110069

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Evidence for Idarucizumab (Pra ...... VERSE AD Full Cohort Analysis.

@en

Evidence for Idarucizumab

@nl

type

Item

label

Evidence for Idarucizumab (Pra ...... VERSE AD Full Cohort Analysis.

@en

Evidence for Idarucizumab

@nl

prefLabel

Evidence for Idarucizumab (Pra ...... VERSE AD Full Cohort Analysis.

@en

Evidence for Idarucizumab

@nl

P1476

Evidence for Idarucizumab (Pra ...... VERSE AD Full Cohort Analysis.

@en

P2093

Nicole E Cieri-Hutcherson

http://www.w3.org/2001/XMLSchema#string

Rajvi Bhatt

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran versus warfarin in patients with atrial fibrillation

Idarucizumab for Dabigatran Reversal

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report

Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report.

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.

Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

P304

692-698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Timothy C Hutcherson

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29089725

http://www.w3.org/2001/XMLSchema#string

P932

5642158

http://www.w3.org/2001/XMLSchema#string